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OVERVIEW
Mammalian memory involves multiple
brain areas and neurotransmitter systems;
both at the receptor and post-receptor
level (Meneses, 2014a,b). Investigations of
serotonin (5-hydroxytryptamine, 5-HT)
involvement in memory (Meneses, 2013)
have been significantly enhanced by the
identification, classification, and cloning
of multiple receptors (Hoyer et al., 1994,
2002) and studies at the post-receptor
level (Raymond et al., 2001). Emergent
investigation of 5-HT7 receptor is grow-
ing but contradictory. Hence, major cur-
rent questions include (1) the paradox that
5-HT7 receptor agonists and antagonists
in behavioral memory tasks are reveal-
ing promnesic and antiamnesic effects;
(2) 5-HT7 and 5-HT1A receptors inter-
action (and other 5-HT receptors), and
neural markers associated to these cog-
nitive processes and individual differ-
ences. In this work recent data are briefly
revised.
5-HT7 RECEPTOR STIMULATION
Freret et al. (2014) reported that with
a 2-h delay, (post-training) administra-
tion of the 5-HT7 receptor antagonist
SB-269970 (3 and 10mg/kg, sc) impaired
the discrimination of the novel object;
but with a 4-h delay, while control mice
were not able to discriminate the novel
object, mice treated with the agonist
5-carboxamidotryptamine (5-CT; display-
ing affinity for several receptors including
5-HT7; Hoyer et al., 1994) showed a sig-
nificant discrimination. This promnesic
effect was blocked by SB-269970, but not
by WAY-100135 or GR-127935 (5-HT1A
or 5-HT1B/1D receptor antagonists,
respectively; Hoyer et al., 1994). Freret
et al. (2014) conclude that 5-HT7 receptor
tonically modulates cognitive processes
involved in consolidation performances in
object recognition and therefore, it could
be a promising target to treat memory dys-
functions (especially episodically related
deficits) or pathological aging. Notably,
Stahl (2010) suggests that 5-HT7 receptor
(blockade) as a novel therapeutic target for
antidepressant and pro-cognitive effects.
Nikiforuk et al. (2013) also conclude that
antagonism of 5-HT7 receptor may rep-
resent a useful pharmacological approach
in the treatment of cognitive deficits and
some negative schizophrenia symptoms.
Also, Tajiri et al. (2012) and Gasbarri and
Pompili (2014) propose that the 5-HT7
receptor is a rational target for the treat-
ment of psychiatric disorders. Certainly,
more research is necessary about 5-HT7
receptor, its functional complexity in
memory formation and abnormal mem-
ory as well timing of drug administration
(McGaugh, 1989; Monleón et al., 2008).
Pre-training elevation of 5-HT by the
selective serotonin reuptake inhibitor
(SSRI) fluoxetine had no effect by itself,
but facilitated passive avoidance when
combined with the 5-HT1A receptor
antagonist NAD-299 and this facilita-
tion was blocked by SB-269970 (Eriksson
et al., 2012). Likewise Eriksson et al.
(2012) reported that a reduced activation
of the 5-HT1A receptor was resulting in
enhanced stimulation of the 5-HT7 recep-
tor but 5-HT7 receptor agonists LP-44 or
AS19 failed to facilitate passive avoidance
performance; and according with these
authors LP-44 and AS19 have low efficacy
to stimulate protein phosphorylation of
5-HT7 receptor-activated signaling cas-
cades. Notably, in the mutant mouse brain
(lacking pituitary adenylate cyclase, an
experimental mouse model for psychi-
atric disorders) 5-HT7 protein expression
did not differ from wild-type mice but
in primary embryonic hippocampal neu-
rons AS-19 increased neurite length and
number (Tajiri et al., 2012). Likewise, LP-
211 and 8-OHDPAT affect neurites in
embryonic cultures (Speranza et al., 2013).
Certainly, Eriksson et al. (2012) propose
that retention (in passive avoidance) is
mediated through hippocampal 5-HT1A
receptor activation, while the 5-HT7
receptor appears to facilitate memory pro-
cesses in a broader cortico-limbic network
and not the hippocampus alone. Notably,
LP-211 rescued diverse defective perfor-
mances, including memory in the novelty
preference task as well as the abnormal
activation of PAK and cofilin (key regula-
tors of actin cytoskeleton dynamics) and
of the ribosomal protein (rp) S6, whose
reduced activation inMECP2mutant neu-
rons is responsible for the altered protein
translational control (De Filippis et al.,
2014). De Filippis et al. (2014) indicate
that pharmacological targeting of 5-HT7
receptor improves specific behavioral and
molecular manifestations and these data
are a first step toward the validation of an
innovative systemic treatment to disorders
associated with intellectual disability.
Importantly, either AS-19 or LP-211
or the dual 5-HT1A/7 receptor agonist,
8-OHDPAT, facilitated memory con-
solidation in an associative memory
task and increased cAMP production
(Pérez-García et al., 2006; Meneses, 2013;
Meneses et al., 2014) which were reversed
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by SB-269970. Certainly, an association
between memory and cAMP produc-
tion exists (Kandel, 2001; Izquierdo et al.,
2006). It should be noted however that
memory formation in an autoshaping
learning (Pérez-García and Meneses,
2008) showed that cAMP production
was decreased by 8-OHDPAT if memory
was improving but the opposite occurred
in absence of memory. In autoshaping
task, trained animals are food-restricted
(at 85% of ad-libitum), receiving one
autoshaping training and are tested at
1.5 h for short-term memory (STM)
and at 24 and 48 h for consolidation
of long-term memory (LTM) (Meneses,
2013). Why 8-OHDPAT improved mem-
ory (consolidation, 48 h) and increased
cAMP in cortex and hippocampus
(Manuel-Apolinar and Meneses, 2004)
or decremented (Pérez-García and
Meneses, 2008) hippocampal cAMP pro-
duction? Importantly, the new 5-HT7
receptor agonist LP-211 did not affect
STM; nonetheless, at 0.5 and 1.0mg/kg
it improved LTM. The 5-HT7 recep-
tor antagonist SB-269970 (10.0mg/kg)
alone had not effect but it reversed the
LP-211 (1.0mg/kg) LTM facilitation.
The scopolamine (0.2mg/kg) induced-
decrement in CR was accompanied by
significant increased cAMP production.
Scopolamine-induced amnesia and incre-
ments in cAMP, are significantly but not
completely reversed by LP-211 (Meneses
et al., 2014). Hence, prefrontal cortex,
cAMP production and improved mem-
ory formation seem to be associated;
however, this association is complex and
dependent on the basal level (e.g., preva-
lent expression of either of 5-HT1A or
5-HT7 receptors). For instance, the time-
course (0–120 h) of autoshaped responses
revealed progressive performance and
mRNA 5-HT1A or 5-HT7 receptors are
monotonically augmented or declined
in prefrontal cortex, hippocampus and
raphe nuclei, respectively (Perez-Garcia
and Meneses, 2009). Moreover, 5-HT1A
receptor is increased, whereas 5-HT7
receptor levels are decreased by aging
(Saroja et al., 2014). Also, they showed
significant correlation with the time
spent in target quadrant; hence accord-
ing with Saroja et al. (2014) these are
two key parameter of memory retrieval
which in turn unambiguously links the
serotonergic receptor system to spatial
memory performance.
5-HT7 RECEPTOR BLOCKADE:
COGNITIVE DEMAND OR MEMORY
IMPAIRED
Gasbarri et al. (2008) showed that
SB-269970 improved memory, decreas-
ing the number of errors in test phase and,
thus, affecting reference memory, while
no effects in working memory; postu-
lating that 5-HT7 receptor blockade had
procognitive effect, when the learning task
implicated a high degree of difficulty. In
addition, the 5-HT7 receptor antagonists,
SB-269970 or DR 4004 alone had no effect
but reversed amnesia induced by scopo-
lamine and dizocilpine (Meneses, 2004).
Hence, 5-HT7 receptor antagonism plays
an important role under poor memory or
when the learning or memory is complex.
5-HT7 BLOCKADE AND PROMISCUOUS
AFFINITY
In recent time, it has become evident
that 5-HT7 blockade and drugs display-
ing promiscuous affinity have interesting
effects. For instance, lurasidone (affinity
for several receptors including 5-HT7)
and the selective 5-HT7 receptor antag-
onist, SB-656104-A improved learning
and memory deficits by dizocilpine (or
MK-801), in the rat passive avoidance
test, and AS-19 (3mg/kg) completely
blocked the attenuating effects of lurasi-
done (3mg/kg); AS-19 (1–10mg/kg)
pre-training administration had no effects
(Horisawa et al., 2013). SB-269970 (30 but
not 10mg/kg) pre-training administra-
tion produces both anti-psychotic-like
(amphetamine- or phencyclidine-induced
hyperactivity tests) and pro-cognitive
(novel object discrimination test) activ-
ity in preclinical animal models (Waters
et al., 2012); these authors conclude that
SB-269970 is more a potent inverse agonist
than SB-258741, which might be a poten-
tial explanation for the conflicting profiles
in vivo (for references see Waters et al.,
2012). Importantly, Huang et al. (2014)
reported that 5-HT1A and 5-HT7 recep-
tors contribute to lurasidone-induced
dopamine efflux, concluding that, at least
partially, 5-HT1A agonist and 5-HT7
antagonist properties may contribute
to reversing schizophrenia-like effects.
Chronic stress impaired performance on
the extra-dimensional (ED) set-shifting
stage of the frontal-dependent atten-
tional set-shifting task and amisulpride
(3mg/kg) before testing reversed this
restraint-induced cognitive inflexibil-
ity and improved ED performance of
the unstressed control group (Nikiforuk
and Popik, 2013). AS-19 (10mg/kg) pre-
training alone had no effect but abolished
the pro-cognitive efficacy of amisulpride
(Nikiforuk and Popik, 2013). Nikiforuk
et al. (2013) also reported that acute
administration of SB-269970 (1mg/kg)
or amisulpride (3mg/kg) ameliorated
ketamine-induced cognitive inflexibility
and novel object recognition deficit in rats;
both compounds were also effective in
attenuating ketamine-evoked disruption
of social interactions. In contrast, nei-
ther SB-269970 nor amisulpride affected
ketamine-disrupted prepulse inhibition;
ketamine is a glutamatergic antagonist
(Neill et al., 2010). Importantly, in contrast
to the negative regulatory effects of long-
term activation of 5-HT7 receptors on
NMDA receptor signaling (in vitro) acute
activation of 5-HT7 receptors promotes
NMDA receptor activity (Vasefi et al.,
2013). Hence, these findings highlight
the potential for temporally differential
regulation of NMDA receptors by the
5-HT7 receptor. While some inconsis-
tencies might be related to the opposite
action exerted by 5-HT1A and 5-HT7
receptors over cAMP production (Renner
et al., 2012; Meneses, 2014a,b); certainly,
in different protocols of training/testing
(memory consolidation vs. STM and
LTM), various brain areas and neuro-
transmission systems interaction might be
also implicated.
5-HT1A AND 5-HT7 RECEPTORS
The functional significance of 5-HT1A and
5-HT7 receptors dimerization is has been
revised (Matthys et al., 2011; Gellynck
et al., 2013; Herrick-Davis, 2013); indicat-
ing that it differentially regulates receptor
signaling and trafficking (Renner et al.,
2012). But still we do not know the
implications of this in memory forma-
tion and amnesic conditions; hence, the
study of signaling associated to 5-HT7
receptor in memory formation, amne-
sia and forgetting might provide signif-
icant insights (Meneses, 2014a,b). For
instance, while the association of 5-HT7
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receptor stimulation, improved memory
and increased cAMP seems to be reliable
findings; certainly factors such as differen-
tial regulation of hippocampal expression
as well as individual differences might be
important (see Meneses, 2013). In addi-
tion, a biphasic and brain-region selective
down-regulation of cAMP concentrations
is observed supporting object recognition
in the rat (Hotte et al., 2012). Wang et al.
(2013) have noted that while it is rela-
tively well established that cAMP signaling
is involved in the mediation of memory,
the reports on its role to date are incon-
sistent. One hypothesis is that overactive
cAMP signaling impairs working mem-
ory in the aged prefrontal cortex (PFC)
or activation of the cAMP signaling in
the frontal cortex is necessary for working
memory; the explanations for this discrep-
ancy may include: (i) activation of cAMP
signaling within the PFC and an inverted
U-shape dose-response on working mem-
ory and memory optimum range of cAMP
rather than an overmuch or scanty pro-
duction; (ii) the continuous and dynamic
updating of cAMP levels occurs at the dif-
ferent time-course of memory formation;
(iii) cAMP activation might be beneficial
for working memory under conditions
that require hippocampal–PFC interac-
tions (Wang et al., 2013). Given the com-
plexity of cAMP-dependent responses;
hence studies of brain areas and individual
differences remain to be reported at both
behavioral and cellular levels (see Wang
et al., 2013).
Evidence exists of individual differ-
ences regarding memory (Ballaz et al.,
2007a,b; Fitzpatrick et al., 2013; Flagel
et al., 2014) and forgetting (Tellez et al.,
2012); hence, it seems reasonable to
suggest that in autoshaping (or sign-
tracking; seeMeneses, 2003) the increment
(Manuel-Apolinar and Meneses, 2004) or
decrement (Pérez-García and Meneses,
2008) cAMP production might be involv-
ing individual differences (e.g., Meneses,
2014a,b). Notably, individual variation in
the magnitude and influence of cue reac-
tivity over behavior in humans and ani-
mals suggest that cue-reactive individuals
may be at greater risk for the progres-
sion to addiction and/or relapse (Anastasio
et al., 2014).
Also, an important implication is
that 5-HT7 (and/or 5-HT1A) receptors
stimulation increased or decreased cAMP
production (e.g., Hoyer et al., 1994)
and improved memory (Meneses et al.,
2014). Likewise, evidence indicates that
5-HT7 splice variants constitutively acti-
vate adenylyl cyclase (Leopoldo et al.,
2011). It should be crucial to confirm if
memory formation, amnesia, or forgetting
by themselves and/or plus drugs modify
adenylyl cyclase.
Hence, (1) memory requires restricted
or selective cAMP production (Pérez-
García and Meneses, 2008; Meneses,
2013); (2) a major and consistent emerg-
ing finding is that 5-HT7 receptor
stimulation seems to facilitate memory
formation and reverse memory impair-
ment; (3) expression of 5-HT7 (and
5-HT1A) receptors are accompanying
memory; (4) the 5-HT7 antagonism
alone had no effect but reversed memory
deficits. Notably, a combination of neural
and cognitive processes may contribute an
early and specificmarker of disorders asso-
ciated to dysfunctional cognitive skills or
memory in psychiatric disorders (Millan
et al., 2012), including Alzheimer’s disease
progression (Ibanez and Parra, 2014).
CONCLUSIONS
Behavioral and molecular studies may be
particularly insightful and timely in view
of the apparently contradictory notion
that either 5-HT1A or 5-HT7 receptor ago-
nists or antagonists are useful in the treat-
ment of learning and memory disorders.
Also, the distinction about normal mem-
ory or impaired memory, timing of drug
administration and individual differences
are providing important insights about
5-HT1A or 5-HT7 receptors stimulation
and blockade.
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